Yarrow Bioscience (NASDAQ:YARW) Stock Short Interest Jumps 123.9%

Yarrow Bioscience (NASDAQ:YARW) was the recipient of a large increase in short interest in the month of September. As of September 15th, there was short interest totaling 126,528 shares, an increase of 123.9% from the August 31st total of 56,499 shares. Based on an average daily volume of 170,937 shares, the short-interest ratio is presently 0.7 days. Currently, 4.9% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. TD Cowen began coverage on shares of Yarrow Bioscience in a report on Tuesday, July 28th. They set a “buy” rating on the stock. Wall Street Zen upgraded Yarrow Bioscience to a “hold” rating in a research report on Saturday, August 22nd. Finally, BTIG Research initiated coverage on Yarrow Bioscience in a research report on Monday, August 3rd. They set a “buy” rating and a $58.00 target price for the company. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $58.00.

Institutional Investors Weigh In On Yarrow Bioscience

Several large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in shares of Yarrow Bioscience during the second quarter worth approximately $29,000. Two Sigma Securities LLC bought a new stake in shares of Yarrow Bioscience during the second quarter valued at approximately $26,000. GSA Capital Partners LLP purchased a new stake in shares of Yarrow Bioscience in the second quarter valued at approximately $47,000. T3 Companies LLC purchased a new stake in shares of Yarrow Bioscience in the fourth quarter valued at approximately $548,000. Finally, Nantahala Capital Management LLC bought a new position in Yarrow Bioscience in the second quarter worth approximately $1,301,400,000. 83.78% of the stock is owned by hedge funds and other institutional investors.

Yarrow Bioscience Stock Performance

YARW stock opened at $25.54 on Friday. The stock has a fifty day simple moving average of $34.10. Yarrow Bioscience has a twelve month low of $16.00 and a twelve month high of $46.95. The stock has a market capitalization of $68.19 million, a price-to-earnings ratio of -1.74 and a beta of 2.01.

Yarrow Bioscience (NASDAQ:YARW) last issued its earnings results on Thursday, August 13th. The company reported ($3.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($3.33). The company had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $0.20 million. Yarrow Bioscience had a negative net margin of 4,726.21% and a negative return on equity of 84.40%.

Yarrow Bioscience Announces Dividend

The business also recently disclosed a special dividend, which was paid on Thursday, July 23rd. Investors of record on Wednesday, July 22nd were issued a dividend of $19.00 per share.

Yarrow Bioscience Company Profile

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.